Azithromycin/hydroxychloroquineQTc prolongation during off-label treatment: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1845卷 / 1期

关键词：

D O I：

10.1007/s40278-021-91978-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：95 / 95

相关论文

共 50 条

[41] RiociguatHypotension during off-label use: case report
[J]. Reactions Weekly, 2023, 1941 (1) : 321 - 321
[42] IvabradineDizziness during off-label use: case report
[J]. Reactions Weekly, 2018, 1691 (1) : 169 - 169
[43] HydroxychloroquineHepatotoxicity following off-label treatment: case report
[J]. Reactions Weekly, 2020, 1812 (1) : 148 - 148
[44] IvabradinePhosphenes during off-label use: case report
[J]. Reactions Weekly, 2018, 1688 (1) : 137 - 137
[45] AmikacinNephrotoxicity during off-label use: case report
[J]. Reactions Weekly, 2022, 1918 (1) : 36 - 36
[46] PembrolizumabNeutropenia following off-label treatment: case report
[J]. Reactions Weekly, 2021, 1851 (1) : 288 - 288
[47] RivoceranibHaemafecia following off-label treatment: case report
[J]. Reactions Weekly, 2018, 1721 (1) : 263 - 263
[48] BexaroteneTransaminitis following an off-label treatment: case report
[J]. Reactions Weekly, 2019, 1741 (1) : 59 - 59
[49] AnakinraToxidermia follwing off-label treatment: case report
[J]. Reactions Weekly, 2019, 1751 (1) : 35 - 35
[50] FavipiravirLack of efficacy and off-label treatment: case report
[J]. Reactions Weekly, 2023, 1981 (1) : 179 - 179

← 1 2 3 4 5 →